The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: Release of a kinetic block by a heterologous protein surface loop

Journal of Molecular Biology

Volumn 293, Issue 3, 1999, Pages 613-627

  Dekker, Rob J ^a   Eichinger, Andreas ^b   Stoop, Allart A ^a   Bode, Wolfram ^b   Pannekoek, Hans ^a   Horrevoets, Anton J G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

Acylation; Crystal structure; Serine protease; SERPIN; Suicide substrate mechanism

Indexed keywords

HIRUGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE; SUICIDE SUBSTRATE; THROMBIN;

ACYLATION; AMINO ACID SUBSTITUTION; ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME KINETICS; HUMAN; MODEL; PRIORITY JOURNAL; STOICHIOMETRY; SURFACE PLASMON RESONANCE;

EID: 0032739834     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1999.3178     Document Type: Article

References (42)

1. Björk I., Nordling K., Olson S. T. Immunologic evidence for insertion of the reactive-bond loop of antithrombin into the A beta-sheet of the inhibitor during trapping of target proteinases. Biochemistry. 32:1993;6501-6505.
2. Bock P. E., Olson S. T., Björk I. Inactivation of thrombin by antithrombin is accompanied by inactivation of regulatory exosite I. J. Biol. Chem. 272:1997;19837-19845.
3. Bode W., Mayr I., Baumann U., Huber R., Stone S. R., Hofsteenge J. The refined 1.9 Å crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 8:1989;3467-3475.
4. Bode W., Turk D., Karshikov A. The refined 1.9 Å X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci. 1:1992;426-471.
5. Brünger A. T., Adams P. D., Clore G. M., DeLano W. L., Gros P., Grosse-Kunstleve R. W., Jiang J.-S., Kuszewski J., Nilges M., Pannu N. S., Read R. J., Rice L. M., Simonson T., Warren G. L. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallog. sect. D. 54:1998;905-921.
6. Bucher J. C. The Numerical Analysis of Ordinary Differential Equations: Runge-Kutta and General Linear Methods. 1987;John Wiley & Sons, Chichester.
7. Acta Crystallog. sect. D. 50:1994;760-763.
8. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb. Haemost. 43:1980;77-89.
9. Ehrlich H. J., Gebbink R. K., Keijer J., Linders M., Preissner K. T., Pannekoek H. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J. Biol. Chem. 265:1990;13029-13035.
10. Ehrlich H. J., Klein-Gebbink R., Preissner K. T., Keijer J., Esmon N., Mertens N., Pannekoek H. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. J. Cell. Biol. 115:1991;1773-1781.
11. Furie B., Bing D. H., Feldmann R. J., Robison D. J., Burnier J. P., Furie B. C. Computer- generated models of blood coagulation factor Xa, factor IXa, and thrombin based upon structural homology with other serine proteases. J. Biol. Chem. 257:1982;3875-3882.
12. Horrevoets A. J. G., Tans G., Smilde A. E., van Zonneveld A.-J., Pannekoek H. Thrombin-variable region 1 (VR1). Evidence for the dominant contribution of VR1 of serine proteases to their interaction with plasminogen activator inhibitor 1. J. Biol. Chem. 268:1993;779-782.
13. Horrevoets A. J. G., Pannekoek H., Nesheim M. E. Production and characterization of recombinant human plasminogen(S741C-fluorescein). A novel approach to study zymogen activation without generation of active protease. J. Biol. Chem. 272:1997;2176-2182.
14. Jones T. A. A graphics model building and refinement system for macromolecules. J. Appl. Crystallog. 11:1978;268-272.
15. Lamba D., Bauer M., Huber R., Fischer S., Rudolph R., Kohnert U., Bode W. The 2.3 Å crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator. J. Mol. Biol. 258:1996;117-135.
16. Lamzin V. S., Wilson K. S. Automated refinement of protein models. Acta Crystallog. sect. D. 49:1993;129-147.
17. Laskowski R. A., MacArthur M. W., Moss D. S., Thornton J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallog. 26:1993;283-291.
18. Le Bonniec B. F., MacGillivray R. T. A., Esmon C. T. Thrombin Glu-39 restricts the P'3 specificity to nonacidfic residues. J. Biol. Chem. 266:1991;13796-13803.
19. Leslie A. G. W. Molecular data processing. Moras D., Podjarny A. D., Thierry J. C. Crystallographic Computing 5. 1991;50-61 Oxford University Press, Oxford.
20. Lijnen H. R., van Hoef B., Collen D. On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator. J. Biol. Chem. 266:1991;4041-4044.
21. Lucore C. L., Sobel B. E. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation. 77:1988;660-669.
22. Madison E. L., Goldsmith E. J., Gerard R. D., Gething M.-J. H., Sambrook J. F. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature. 339:1989;721-724.
23. Madison E. L., Goldsmith E. J., Gerard R. D., Gething M.-J. H., Sambrook J. F., Bassel-Duby R. S. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. Proc. Natl Acad. Sci. USA. 87:1990a;3530-3533.
24. Madison E. L., Goldsmith E. J., Gething M.-J. H., Sambrook J. F., Gerard R. D. Restoration of serine protease-inhibitor interaction by protein engineering. J. Biol. Chem. 265:1990b;21423-21426.
25. Murshudov G. N., Vagin A. A., Dodson E. J. Refinement of macromolecular structures by the maximum likelihood method. Acta Crystallog. sect. D. 53:1997;240-255.
26. Nicholls A., Sharp K., Honig B. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins: Struct. Funct. Genet. 11:1991;281-296.
27. Olson S. T. Heparin and ionic strength-dependent conversion of antithrombin III from an inhibitor to a substrate of alpha-thrombin. J. Biol. Chem. 260:1985;10153-10160.
28. Olson S. T., Shore J. D. Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. J. Biol. Chem. 261:1986;13151-13159.
29. Olson S. T., Bock P. E., Kvassman J., Shore J. D., Lawrence D. A., Ginsburg D., Björk I. Role of the catalytic serine in the interactions of serine proteinases with protein inhibitors of the serpin family. Contribution of a covalent interaction to the binding energy of serpin-proteinase complexes. J. Biol. Chem. 270:1995;30007-30017.
30. Patston P. A., Gettins P., Beechem J. M., Schapira M. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. Biochemistry. 30:1991;8876-8882.
31. Payne M. H., Krstenansky J. L., Yates M. T., Mao S. J. Positional effects of sulfation in hirudin and hirudin PA related anticoagulant peptides. J. Med. Chem. 34:1991;1184-1187.
32. Renatus M., Engh R. A., Stubbs M. T., Huber R., Fischer S., Kohnert U., Bode W. Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA. EMBO J. 16:1997a;4797-4805.
33. Renatus M., Bode W., Huber R., Stürzebecher J., Prasa D., Fischer S., Kohnert U., Stubbs M. T. Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator. Implications for the design of low molecular weight substrates and inhibitors. J. Biol. Chem. 272:1997b;21713-21719.
34. Rezaie A. R. Elucidation of the structural basis for the slow reactivity of thrombin with plasminogen activator inhibitor-1. Biochemistry. 37:1998;13138-13142.
35. Shore J. D., Day D. E., Francis-Chmura A. M., Verhamme I., Kvassman J., Lawrence D. A., Ginsburg D. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J. Biol. Chem. 270:1995;5395-5398.
36. Sipley J. D., Alexander D. S., Testa J. E., Quigley J. P. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1. Proc. Natl Acad. Sci. USA. 94:1997;2933-2938.
37. Skrzypczak-Jankun E., Carperos V. E., Ravichandran K. G., Tulinsky A., Westbrook M., Maraganore J. M. Structure of the hirugen and hirulog 1 complexes of α-thrombin. J. Mol. Biol. 221:1991;1379-1393.
38. Spraggon G., Phillips C., Nowak U. K., Ponting C. P., Saunders D., Dobson C. M., Stuart D. I., Jones E. Y. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure. 3:1995;681-691.
39. Tans G., Janssen-Claessen T., Hemker H. C., Zwaal R. F., Rosing J. Meizothrombin formation during factor Xa-catalyzed prothrombin activation. Formation in a purified system and in plasma. J. Biol. Chem. 266:1991;21864-21873.
40. van Meijer M., Roelofs Y., Neels J., Horrevoets A. J. G., van Zonneveld A.-J., Pannekoek H. Selective screening of a large phage display library of plasminogen activator inhibitor 1 mutants to localize interaction sites with either thrombin or the variable region 1 of tissue-type plasminogen activator. J. Biol. Chem. 271:1996;7423-7428.
41. van Meijer M., Smilde A. E., Tans G., Nesheim M. E., Pannekoek H., Horrevoets A. J. G. The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin. Blood. 90:1997;1874-1882.
42. Wilczynska M., Fa M., Ohlsson P. I., Ny T. The inhibition mechanism of serpins. Evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor complex. J. Biol. Chem. 270:1995;29652-29655.